Skip to main
ATXS

Astria Therapeutics (ATXS) Stock Forecast & Price Target

Astria Therapeutics (ATXS) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 17%
Buy 50%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Astria Therapeutics is positioned positively due to the well-tolerated nature of its product candidates, particularly STAR-0310, which has demonstrated a wider therapeutic window and the potential for greater efficacy than earlier OX40 antibodies. The anticipated synergy with BioCryst’s existing commercial infrastructure is expected to drive operating profits from its assets, particularly following the launch of navenibart in the hereditary angioedema market. Additionally, the company enjoys a large commercial market opportunity, alongside significant upcoming news flow, which is likely to support strategic growth and enhance the overall pipeline.

Bears say

Astria Therapeutics Inc faces significant challenges that contribute to a negative outlook regarding its stock. The company is at risk of failed or inconclusive clinical trials for its product candidates, STAR-0215 and STAR-0310, which could hinder progress in drug development. Additionally, there are concerns about the company's ability to secure adequate funding, which is critical for continuing operations and reaching clinical milestones, further exacerbating uncertainties surrounding its valuation.

Astria Therapeutics (ATXS) has been analyzed by 6 analysts, with a consensus rating of Buy. 17% of analysts recommend a Strong Buy, 50% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Astria Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Astria Therapeutics (ATXS) Forecast

Analysts have given Astria Therapeutics (ATXS) a Buy based on their latest research and market trends.

According to 6 analysts, Astria Therapeutics (ATXS) has a Buy consensus rating as of Jan 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Astria Therapeutics (ATXS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.